TRANSBIOBC

Translation of novel Biomarkers for Bladder Cancer for clinical outcome prediction

Coordinatore	"BIOMEDICAL RESEARCH FOUNDATION, ACADEMY OF ATHENS"    more  Organization address address: Soranou Efesiou 4 city: ATHENS postcode: 11527 contact info Titolo: Mr. Nome: Dimitris Cognome: Raptis Email: send email Telefono: +30 2106597574
Nazionalità Coordinatore	Greece [EL]
Totale costo	4˙181˙538 €
EC contributo	3˙260˙358 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2013-INNOVATION-2
Funding Scheme	CP-FP
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-09-01   -   2016-08-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	"BIOMEDICAL RESEARCH FOUNDATION, ACADEMY OF ATHENS"  Organization address address: Soranou Efesiou 4 city: ATHENS postcode: 11527 contact info Titolo: Mr. Nome: Dimitris Cognome: Raptis Email: send email Telefono: +30 2106597574	EL (ATHENS)	coordinator	760˙964.80
2	MOSAIQUES DIAGNOSTICS GMBH  Organization address address: Mellendorfer Strasse 7-9 city: HANNOVER postcode: 30625 contact info Titolo: Prof. Nome: Harald Cognome: Mischak Email: send email Telefono: +49 511 55474413 Fax: +49 511 55474431	DE (HANNOVER)	participant	1˙119˙089.00
3	DIAGNOSWISS SA  Organization address address: ZI LES ILETTES SECTEUR 4 city: MONTHEY postcode: 1870 contact info Titolo: Dr. Nome: Frédéric Cognome: Reymond Email: send email Telefono: +41 244738111 Fax: +41 244738112	CH (MONTHEY)	participant	831˙344.00
4	FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III  Organization address address: CALLE MELCHOR FERNANDEZ ALMAGRO 3 city: MADRID postcode: 28029 contact info Titolo: Ms. Nome: Lilit Cognome: Manukyan Email: send email Telefono: +34 912246900	ES (MADRID)	participant	548˙960.80

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Currently, clinical diagnosis and monitoring of bladder cancer (BC) relies on invasive, highly costly cystoscopy. Additionally, due to high recurrence rates BC treatment is associated with frequent follow-up of patients, making BC one of the most costly types of cancer in terms of management cost. Thus there is a clear clinical need for the development of new approaches for early detection of recurrence and progression. Our proposal is based on the identification of novel biomarkers (BM) for BC recurrence and progression in urine and powerful technological platforms as extensive foreground work of the involved partners in the framework of FP7 EU projects DECanBio and GENINCA. The objective of TransBioBC is to translate this foreground work in the field of BC and to specifically employ the involved technologies (CE-MS and micro-ELISA), represented by the participating SMEs, for the development of non-invasive urine tests for routine monitoring of BC recurrence and progression. Our project uniquely integrates leading BC clinical experts with experts on proteome analysis and high throughput immunoassay development in an implementation-oriented workflow. Strict monitoring of assay analytical performance, and properly collected and well characterized clinical samples from existing sufficiently powered BC cohorts are combined with in-depth knowledge of regulatory requirements, analysis approaches to define added value and well designed business plans including multi-stakeholder dissemination and exploitation plans. Collectively, TransBioBC will provide strong evidence for utility of the new BM directly in BC clinical management and as a secondary aim for usage in clinical trials and drug development.'